文献速递腹部介入US

真实世界研究:超声引导下经皮非靶向肝活检针故障与病理样本质量评估——端切针与侧切针比较

A real-world study evaluating ultrasound-guided percutaneous non-targeted liver biopsy needle failures and pathology sample-quality assessment in both end-cut and side-notch needles.
PubMed 文献 · Br J Radiol · 2021-07-28

该研究纳入2016至2018年间1004例超声引导下非靶向肝活检患者,比较16G端切针Biopince™与侧切针Bard™的针故障率、并发症及样本质量。结果显示端切针故障率显著高于侧切针(8.7% vs 2.9%,p<0.001),但无故障导致并发症;样本长度>20 mm时90.2%可获得>10个门管区,端切针达到该目标的比例显著高于侧切针(71.1% vs 38.5%,p=0.004)。结论认为超声引导肝活检安全,获得>20 mm组织条时样本质量稳定良好。

要点

  • 端切针故障率显著高于侧切针,但针故障未导致并发症。
  • 样本长度>20 mm时90.2%可获得>10个门管区,样本质量稳定。
  • 端切针达到>10个门管区的比例显著高于侧切针。

局限性

  • 原文未明确报告研究是否为单中心或回顾性设计。
  • 研究仅比较了两种特定16G活检针,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To determine biopsy device failures, causative factors, complications and sample quality of the 16G end-cut Biopince™ and side-notch Bard™ needles.

METHODS: All ultrasound-guided non-targeted liver biopsies between 01/01/2016 and 31/12/2018 were included. Operator, device, number of failures, complications and repeat biopsies were recorded. Histopathology samples were reviewed for all cases of needle failure and a group with no failures, and graded "yes/no" for the presence of steatosis, inflammation and fibrosis. The pathology slides from these cases were reviewed to assess biopsy sample quality (length and portal tract number). The failure and no-failure groups were compared in terms of device type/histology, and sample quality was compared between the needle types.

RESULTS: 1004 patients were included. 93.8% (n = 942) required one needle pass to obtain a sample and 6.2% (n = 62) required >1 pass due to needle failure. Total of 76 needle failures, more with end-cut than side-notch needles (8.7% vs 2.9%) (p < 0.001). No needle failures resulted in complication. The presence of liver fibrosis was associated with fewer needle failures (p = 0.036). The major complication rate was 0.4% (4/1044). A biopsy with >10 portal tracts was obtained in 90.2% of specimens > 20 mm long, compared with 66% of 16-20 mm biopsies and 21% of <16 mm biopsies. The target of >10 portal tracts was achieved in 10/26 (38.5%) of side-notch biopsies and 64/90 (71.1%) of end-cut biopsies (p = 0.004).

CONCLUSION: Ultrasound-guided liver biopsy is safe and sample quality is consistently good when a core >20 mm long is obtained. The end-cut biopsy device generated reliably good quality biopsy samples; however, the needle failure rate was significantly higher than the side-cut needle.

ADVANCES IN KNOWLEDGE: Ultrasound-guided liver biopsy specimen quality is consistently good when a core >20 mm long is obtained which can be achieved with a single pass using the 16G BiopinceTM end-cut needle, although the needle failure rate is significantly higher than the 16G Max-Core™ Bard™ side-notch needle.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhong J, Allard R, Hewitson D, et al. A real-world study evaluating ultrasound-guided percutaneous non-targeted liver biopsy needle failures and pathology sample-quality assessment in both end-cut and side-notch needles. Br J Radiol. 2021. PMID: 34289324. doi:10.1259/bjr.20210475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。